The Experts below are selected from a list of 195 Experts worldwide ranked by ideXlab platform
Remco Van Doorn - One of the best experts on this subject based on the ideXlab platform.
-
Promoter CpG island hypermethylation in Dysplastic Nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.
The Journal of investigative dermatology, 2014Co-Authors: Linda Gao, Karin Van Den Hurk, Peter T.m. Moerkerk, Jelle J. Goeman, Samuel Beck, Nelleke A. Gruis, Joost Van Den Oord, Véronique Winnepenninckx, Manon Van Engeland, Remco Van DoornAbstract:Dysplastic nevi are melanocytic lesions that represent an intermediate stage between common Nevus and melanoma. Histopathological distinction of Dysplastic Nevus from melanoma can be challenging and there is a requirement for molecular diagnostic markers. In this study, we examined promoter CpG island methylation of a selected panel of genes, identified in a genome-wide methylation screen, across a spectrum of 405 melanocytic neoplasms. Promoter methylation analysis in common nevi, Dysplastic nevi, primary melanomas, and metastatic melanomas demonstrated progressive epigenetic deregulation. Dysplastic nevi were affected by promoter methylation of genes that are frequently methylated in melanoma but not in common nevi. We assessed the diagnostic value of the methylation status of five genes in distinguishing primary melanoma from Dysplastic Nevus. In particular, CLDN11 promoter methylation was specific for melanoma, as it occurred in 50% of primary melanomas but in only 3% of Dysplastic nevi. A diagnostic algorithm that incorporates methylation of the CLDN11, CDH11, PPP1R3C, MAPK13, and GNMT genes was validated in an independent sample set and helped distinguish melanoma from Dysplastic Nevus (area under the curve 0.81). Melanoma-specific methylation of these genes supports the utility as epigenetic biomarkers and could point to their significance in melanoma development.
Douglas Grossman - One of the best experts on this subject based on the ideXlab platform.
-
the Dysplastic Nevus from historical perspective to management in the modern era part i historical histologic and clinical aspects
Journal of The American Academy of Dermatology, 2012Co-Authors: Keith L Duffy, Douglas GrossmanAbstract:Since its description in the 1970s, the Dysplastic Nevus has been a source of confusion, and whether it represents a precursor to melanoma remains a controversial subject. Although a Consensus Conference in 1992 recommended that the term "Dysplastic Nevus" no longer be used, the histologic diagnosis continues to present a therapeutic quandary for dermatologists and other physicians, and there remains significant variation in clinical management. In part I of this continuing medical education review, we will discuss the historical origins of the term, the evidence for its distinct histologic basis, and its clinical significance.
-
the Dysplastic Nevus from historical perspective to management in the modern era part ii molecular aspects and clinical management
Journal of The American Academy of Dermatology, 2012Co-Authors: Keith L Duffy, Douglas GrossmanAbstract:The Dysplastic Nevus is a discreet histologic entity that exhibits some clinical and histologic features overlapping with common nevi and melanoma. These overlapping features present a therapeutic challenge, and with a lack of accepted guidelines, the management of Dysplastic nevi remains a controversial subject. Although some differences between Dysplastic and common nevi can be detected at the molecular level, there are currently no established markers to predict biologic behavior. In part II of this continuing medical education article, we will review the molecular aspects of Dysplastic nevi and their therapeutic implications. Our goal is to provide the clinician with an up-to-date understanding of this entity to facilitate clinical management of patients with nevi that have histologic dysplasia.
Linda Gao - One of the best experts on this subject based on the ideXlab platform.
-
Promoter CpG island hypermethylation in Dysplastic Nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.
The Journal of investigative dermatology, 2014Co-Authors: Linda Gao, Karin Van Den Hurk, Peter T.m. Moerkerk, Jelle J. Goeman, Samuel Beck, Nelleke A. Gruis, Joost Van Den Oord, Véronique Winnepenninckx, Manon Van Engeland, Remco Van DoornAbstract:Dysplastic nevi are melanocytic lesions that represent an intermediate stage between common Nevus and melanoma. Histopathological distinction of Dysplastic Nevus from melanoma can be challenging and there is a requirement for molecular diagnostic markers. In this study, we examined promoter CpG island methylation of a selected panel of genes, identified in a genome-wide methylation screen, across a spectrum of 405 melanocytic neoplasms. Promoter methylation analysis in common nevi, Dysplastic nevi, primary melanomas, and metastatic melanomas demonstrated progressive epigenetic deregulation. Dysplastic nevi were affected by promoter methylation of genes that are frequently methylated in melanoma but not in common nevi. We assessed the diagnostic value of the methylation status of five genes in distinguishing primary melanoma from Dysplastic Nevus. In particular, CLDN11 promoter methylation was specific for melanoma, as it occurred in 50% of primary melanomas but in only 3% of Dysplastic nevi. A diagnostic algorithm that incorporates methylation of the CLDN11, CDH11, PPP1R3C, MAPK13, and GNMT genes was validated in an independent sample set and helped distinguish melanoma from Dysplastic Nevus (area under the curve 0.81). Melanoma-specific methylation of these genes supports the utility as epigenetic biomarkers and could point to their significance in melanoma development.
Thomas M Runger - One of the best experts on this subject based on the ideXlab platform.
-
repair of directly and indirectly uv induced dna lesions and of dna double strand breaks in cells from skin cancer prone patients with the disorders Dysplastic Nevus syndrome or basal cell Nevus syndrome
Recent results in cancer research, 1997Co-Authors: Thomas M Runger, Bernd Epe, Karin Moller, Barbara Dekant, D HellfritschAbstract:Hereditary disorders carrying an increased skin cancer risk, such as xeroderma pigmentosum (XP), Dysplastic Nevus syndrome (DNS), or basal cell Nevus syndrome (BCNS), are valuable model systems that might provide insights into general mechanisms of skin carcinogenesis. This is especially true of XP, in which a defective repair of UV-induced DNA damage explains the increased risk of basal cell carcinomas, squamous cell carcinomas, and malignant melanomas in UV-exposed skin of affected patients (Kraemer et al. 1987; Barnes et al. 1993; Hoijmakers 1993).
Bert J. Vermeer - One of the best experts on this subject based on the ideXlab platform.
-
Dysplastic nevi. Occurrence in first- and second-degree relatives of patients with 'sporadic' Dysplastic Nevus syndrome.
Archives of dermatology, 1991Co-Authors: M B Crijns, J Vink, Wilma Bergman, Colette L. M. Van Hees, Bert J. VermeerAbstract:• In this study a cross-sectional survey was undertaken among 156 living family members of 31 probands originally classified as having sporadic (histologically verified) Dysplastic Nevus syndrome (DNS). Seven (13.2%) of 53 parents had clinically recognizable DNS. Twenty-six (36.1%) of the 72 sibs showed Dysplastic nevi. The diagnosis of DNS in family members was based on mainly clinical examination; in eight family members—those with only mild manifestation of DNS—a Nevus was removed for histologic confirmation. After correction for pedigree size, we found that 60% of patients with "type A sporadic" DNS actually had one or more relatives with a DNS phenotype. Only 25% (8/30) of the probands were ultimately true sporadic cases without a DNS-affected first- or second-degree relative. In 15% (5/31) of the probands no conclusions concerning the type of DNS could be made because the pedigree size did not allow such a conclusion. We also found a higher prevalence of Dysplastic nevi among the younger generation as compared with the older generation in our probands with DNS and their families as well as in a general population study of 400 individuals. This generation-dependent difference in expression of the DNS phenotype suggests that besides a genetic factor, other factors may play a role in the development of the characteristic phenotype. ( Arch Dermatol. 1991;127:1346-1351)